Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role

Cancer Biomarkers

Volumn 16, Issue 2, 2016, Pages 275-280

  Trapasso, S ^a   Garozzo, A ^a   Belfiore, A ^a   Allegra, E ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

laryngeal cancer; saliva; sCD44var (v6); Soluble CD44

Indexed keywords

SOLUBLE FRACTION OF THE CD44 ISOFORM V6 PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; CD44V6 ANTIGEN; HERMES ANTIGEN;

ADULT; ARTICLE; CANCER PATIENT; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RETROSPECTIVE STUDY; SALIVA ANALYSIS; STUDY DESIGN; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA; LARYNGEAL NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; SALIVA; TUMOR VOLUME;

AGED; ANTIGENS, CD44; BIOMARKERS, TUMOR; CARCINOMA; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALIVA; TUMOR BURDEN;

EID: 84961201363     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150565     Document Type: Article

References (36)

1. A. Garozzo, E. Allegra, A. La Boria, N. Lombardo, Modified supracricoid laryngectomy, Otolaryngol Head Neck Surg 142(1) (2010), 137-139.
2. C. Liang, L. Hongyan, Z. Zhili et al, CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis, Tohoku J Exp Med 232 (2014), 9C-1D94.
3. D. Tarin, Abnormal CD44 gene expression in neoplasia: biological and clinical implications. In: Tahara E, ed. Molecular Pathology of Gastroenterological Cancer, (1997), 171-185.
4. E. Allegra and S. Trapasso, Cancer stem cells in head and neck cancer, Onco Targets Ther 5 (2012), 375-83.
5. E. Allegra, L. Puzzo, V. Zuccalà, S. Trapasso, E. Vasquez, A. Garozzo, R. Caltabiano, Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status, World J Surg Oncol 10 (2012), 206.
6. E. Allegra, N. Lombardo, A. La Boria, G. Rotundo, M.R. Bianco, T. Barrera, M. Cuccunato, A. Garozzo, Quality of voice evaluation in patients treated by supracricoid laryngectomy and modified supracricoid laryngectomy, Otolaryngol Head Neck Surg 145(5) (2011), 789-95.
7. E. Allegra, P. Ferrise, S. Trapasso, O. Trapuzzano, A. Barca, S. Tamburrini, A. Garozzo, Early glottic cancer: Role of MRI in the preoperative staging, Biomed Res Int 2014 (2014), 890385.
8. E. Allegra, R. Caltabiano, A. Amorosi, E. Vasquez, A. Garozzo, L. Puzzo, Expression of BMI1 and p16 in laryngeal squamous cell carcinoma, Head Neck 35(6) (2013), 847-51.
9. E. Allegra, S. Trapasso, A. La Boria, T. Aragona, D. Pisani, A. Belfiore, A. Garozzo, Prognostic role of salivary CD44sol levels in the follow-up of laryngeal carcinomas, J Oral Pathol Med 43(4) (2014), 276-81.
10. E. Allegra, S. Trapasso, A. Sacco, T. Aragona, A. Garozzo, Elisa Detection of Salivary Levels of Cd44sol as a Diagnostic Test for Laryngeal Carcinomas, J Cancer Sci Ther 4(10) (2012), 330-334.
11. E. Allegra, S. Trapasso, D. Pisani, L. Puzzo, The role of BMI1 as a biomarker of cancer stem cells in head and neck cancer: A review, Oncology 86(4) (2014), 199-205.
12. E. Allegra, T. Franco, R. Domanico, A. La Boria, S. Trapasso, A. Garozzo, Effectiveness of therapeutic selective neck dissection in laryngeal cancer, ORL J Otorhinolaryngol Relat Spec 76(2) (2014), 89-97.
13. E. Allegra, T. Franco, S. Trapasso, R. Domanico, A. La Boria, A. Garozzo, Modified supracricoid laryngectomy: Oncological and functional outcomes in the elderly, Clin Interv Aging 7 (2012), 475-80.
14. E.J. Franzmann, E.P. Reategui, F. Pedroso et al, Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer, Cancer Epidemiol Biomarkers Prev 16 (2007), 1348-1355.
15. E.J. Franzmann, E.P. Reategui, K.L. Carraway, K.L. Hamilton, D.T.Weed, W.J. Goodwin, Salivary soluble CD44: A potential molecular marker for head and neck cancer, Cancer Epidemiol Biomarkers Prev 14(3) (2005), 735-9.
16. E.J. Franzmann, E.P. Reategui, L.H. Pereira, F. Pedroso et al, Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma, Head Neck 34(5) (2012), 687-95.
17. E.M. Kittl, R. Ruckser, S. Selleny et al, Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients, Exp Clin Immunogenet 14 (1997), 264-272.
18. G. Güler, S. Saraç, A. Uner, E. Karabulut, A. Ayhan, O. Hiroshi, Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas, Arch Otolaryngol Head Neck Surg 128(4) (2002), 393-7.
19. H.L. Van Hal, G.A.Van Dongen, C.B. Ten Brink et al, Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma, Clin Cancer Res 5 (1999), 3534-354.
20. I. Yüce, A. Bayram, S. Caʇli, O. Canöz, S. Bayram, E. Güney, The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma, Am J Otolaryngol 32(2) (2011), 141-6.
21. J. Chen, J. Zhou, J. Lu, H. Xiong, X. Shi, L. Gong, Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis, BMC Cancer 14 (2014), 15.
22. J. Ostwald, O. Pracht, E. Rhode, B. Kramp, Sind die Produkte der Exons v5 und v6 von CD44 Marker für die Metastasierung von Larynxkarzinomen? Laryngo-Rhino-Otol 76(5) (1997), 295-299.
23. J. Spafford, Z. Pan, P.G. Archer, A.D. Meyers, W.A. Franklin, Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma, Arch Otolaryngol Head Neck Surg 122 (1996), 627-632.
24. J.V. Mulder, P.M. Kruyt, M. Sewnath et al, Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins, Lancet 344 (1994), 1470-1472.
25. L. Chai, H. Liu, Z. Zhang, F. Wang, Q. Wang, S. Zhou, S. Wang, CD44 expression is predictive of poor prognosis in pharyngolaryngeal cancer: systematic review and metaanalysis, Tohoku J Exp Med 232(1) (2014), 9-19.
26. M. Andratschke, S. Chaubal, C. Pauli et al, Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer, Anticancer Res 25 (2005), 2821-2826.
27. M. Brandwein-Gensler and R.V. Smith, Prognostic indicators in head and neck oncology including the new 7th edition of theAJCC staging system, Head Neck Pathol 4(1) (2010), 53-61.
28. M. Kaufmann, K.H. Heider, H.S. Sinn et al, CD44 variant exon epitopes in primary breast cancer and length of survival, Lancet 345 (1995), 615-619.
29. M.C. De Jong, J. Pramana, E.J. Van der Wal et al, CD44 expression predicts local recurrence after radiotherapy in larynx cancer, ClinCancer Res 16(21) (2013), 5329-38.
30. N. Yamane, S. Tsujitani, M.Makino et al, Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer, Oncology 56 (1999), 232-238.
31. S. Trapasso, E. Allegra, Role of CD44 as a marker of cancer stem cells in head and neck cancer, Biologics 6 (2012), 379-83.
32. S.J. Wang, G. Wong, A.M. De Heer, W. Xia, L.Y. Bourguignon, CD44 variant isoforms in head and neck squamous cell carcinoma progression, Laryngoscope 119(8) (2009), 1518-30.
33. T. Kawano, S. Yanoma, Y. Nakamura et al, Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer, Acta Otolaryngol 125 (2005), 392-397.
34. X. Guo, X. Li, F. Li, S. Feng et al, Expression of gene BRMS1 and CD44v6 protein in supraglottic laryngeal carcinoma and its clinical significance, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 23(6) (2009), 249-53.
35. Y. Matsumura and D. Tarin, Significance of CD44 gene products for cancer diagnosis and disease evaluation, Lancet 340 (1992), 1053-1058.
36. Z. Amirghofran, S. Jalali, S.V. Hosseini et al, Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: Soluble forms in relation to tumor tissue expression and metastasis, J. Gastrointest. Cancer 39 (2008), 73-78.